Latest news with #IQVIA
Yahoo
4 hours ago
- Business
- Yahoo
West Pharmaceutical Services (WST) Q2 Earnings Report Preview: What To Look For
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be announcing earnings results this Thursday morning. Here's what you need to know. West Pharmaceutical Services beat analysts' revenue expectations by 2% last quarter, reporting revenues of $698 million, flat year on year. It was a very strong quarter for the company, with a solid beat of analysts' EPS estimates and full-year revenue guidance beating analysts' expectations. Is West Pharmaceutical Services a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting West Pharmaceutical Services's revenue to grow 3.4% year on year to $725.9 million, a reversal from the 6.9% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.51 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. West Pharmaceutical Services has missed Wall Street's revenue estimates four times over the last two years. Looking at West Pharmaceutical Services's peers in the life sciences tools & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Medpace delivered year-on-year revenue growth of 14.2%, beating analysts' expectations by 11.3%, and IQVIA reported revenues up 5.3%, topping estimates by 1.2%. Medpace traded up 54.6% following the results. Read our full analysis of Medpace's results here and IQVIA's results here. Investors in the life sciences tools & services segment have had steady hands going into earnings, with share prices flat over the last month. West Pharmaceutical Services is up 1.1% during the same time and is heading into earnings with an average analyst price target of $278.84 (compared to the current share price of $219). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
10 hours ago
- Business
- Yahoo
S&P 500 Gains & Losses Today: Homebuilder Stocks Soar; Lockheed Martin Loses Altitude
Major U.S. equities indexes were mixed Tuesday as investors reacted to the latest earnings reports and prepared for Big Tech results due tomorrow. The S&P 500 ticked around 0.1% higher, notching a record closing high for a second straight session. The Dow was up 0.4%, while the Nasdaq fell 0.4%, the latter ending a six-session streak of record closes with its first down day in more than a week. Read Investopedia's full coverage of today's trading here. IQVIA Holdings (IQV) shares soared 18%, securing the S&P 500's top performance on Tuesday. The data analytics and clinical research solutions provider topped second-quarter sales and profit estimates and issued a better-than-expected full-year forecast. IQVIA's strategic collaborations and strength in artificial intelligence, including the development of more than 50 AI agents set for launch in the third quarter, have helped boost the company's position in the life sciences sector. D.R. Horton (DHI) and PulteGroup (PHM) reported quarterly sales and profits that came in ahead of expectations, and shares of the homebuilders surged 17% and about 12%, respectively. Despite the results, both companies recognized the impact of soft sentiment among potential homebuyers, with elevated mortgage rates and tariffs pressuring affordability. D.R. Horton's executive chairman predicted that sales incentives will stay elevated and increase heading into the year. Shares of Lennar (LEN) rose more than 8%. Northrop Grumman (NOC) shares jumped 9.4% after the aerospace and defense firm posted higher-than-expected sales and profits for the second quarter. Demand for military aircraft and defense systems driven by heightened geopolitical tensions contributed to the performance, and Northrop could be positioned to benefit from an increased focus on high-tech missiles and drones in President Donald Trump's military budget for next year. The report from Northrop rival Lockheed Martin (LMT) was not as well-received. Lockheed shares tumbled 11%, falling the furthest of any stock in the benchmark index, after the company disclosed $1.6 billion in losses related primarily to a classified aeronautics program and an international helicopter program. Quarterly revenue fell short of consensus estimates, and Lockheed reduced its full-year profit guidance. Tobacco giant Philip Morris (PM) missed quarterly revenue expectations, reflecting an ongoing decline in demand for cigarettes. Although the company raised its outlook for full-year adjusted profits, it lowered its forecasts for cigarette and smoke-free shipment volumes. Phillip Morris shares sank 8.4% on Tuesday. Although MSCI (MSCI) exceeded quarterly sales and profit forecasts, boosted by growth in recurring subscription revenue and asset-based fees, shares of the financial data provider and market index creator slipped about 9%. Read the original article on Investopedia Sign in to access your portfolio
Yahoo
10 hours ago
- Business
- Yahoo
Why Are Fortrea (FTRE) Shares Soaring Today
What Happened? Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) jumped 24.1% in the afternoon session after positive earnings reports from industry peers lifted the entire contract research organization sector. The rally was sparked by strong second-quarter results from two major players in the space, IQVIA and Medpace, which both reported earnings and revenue that beat analyst expectations. Medpace, in particular, surged after significantly raising its full-year guidance for revenue and earnings. This wave of good news from competitors boosted investor confidence across the sector, leading to gains for other contract research organizations (CROs) like Fortrea. A CRO provides outsourced research and development services to the pharmaceutical and biotechnology industries. Fortrea is scheduled to report its own second-quarter financial results on August 6, 2025. Is now the time to buy Fortrea? Access our full analysis report here, it's free. What Is The Market Telling Us Fortrea's shares are extremely volatile and have had 53 moves greater than 5% over the last year. But moves this big are rare even for Fortrea and indicate this news significantly impacted the market's perception of the business. The previous big move we wrote about was 4 days ago when the stock dropped 9.2% as several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities. Fortrea is down 68.9% since the beginning of the year, and at $5.80 per share, it is trading 79.2% below its 52-week high of $27.88 from July 2024. Investors who bought $1,000 worth of Fortrea's shares at the IPO in June 2023 would now be looking at an investment worth $192.69. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
13 hours ago
- Business
- Yahoo
IQVIA Leads S&P 500 Gainers on Better-Than-Expected Earnings
IQVIA Holdings (IQV) stock surged on Tuesday after the clinical research and analytics company's second-quarter results topped estimates. Shares jumped 18% to lead gainers on the S&P 500 after North Carolina-based IQVIA said it earned an adjusted $2.81 per share in the latest period, while revenue rose 5% from the same time a year ago to $4.02 billion, each above the analyst consensus compiled by Visible Alpha. However, IQVIA narrowed its full-year forecasts, projecting revenue of $16.1 billion to $16.3 billion, compared with the previous range of $16 billion to $16.4 billion, while adjusted EPS is now expected to come in between $11.75 and $12.05, down from $11.70 to $12.10 previously. Sales grew across all three of IQVIA's segments, as CEO Ari Bousbib said the results "underscore the resilience of our global diversified portfolio." Accounting for Tuesday's advance, IQVIA shares were $188.57 in recent trading, still within less than 5% of where it started the year. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 hours ago
- Business
- Yahoo
IQVIA Holdings (IQV) Updates 2025 Revenue Guidance and Completes Share Buyback
IQVIA Holdings recently updated its earnings guidance for 2025 with expectations of revenue ranging between $16,100 million and $16,300 million. This update coincides with the company's Q2 earnings announcement, showing an increase in sales to $4,017 million but a decline in net income to $266 million. During the last quarter, IQVIA's share price rose 11%, likely supported by its ongoing share buyback program, where the company repurchased 3,985,000 shares. Despite the broader market fluctuations amid record highs reached by the S&P 500 and Nasdaq, IQVIA's proactive measures appear aligned with its recent share price uptick. We've discovered 1 weakness for IQVIA Holdings that you should be aware of before investing here. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. The recent update in IQVIA Holdings' earnings guidance and its ongoing share buyback program suggest a focused strategy to enhance shareholder value, aligning with the uptick in its share price. However, the total return including share price and dividends over the past five years shows a 2.05% decline, indicating challenges in achieving sustainable long-term growth. This performance contrasts with the broader market's one-year performance, where IQVIA underperformed the US Life Sciences industry, which itself experienced a 22% decline. The company's anticipated revenue range of US$16.1 billion to US$16.3 billion by 2025 and partnerships like those with NVIDIA could provide a cost advantage and potentially elevate margins, important factors amid macroeconomic pressures. Analysts foreseeing revenue growth of 5.2% annually over the next three years could see risks should sector funding conditions deteriorate. The current share price is below the consensus price target of US$190.67, suggesting potential for appreciation if earnings and revenue forecasts materialize as expected, though differing analyst views present varying degrees of confidence in this forecast. Understand IQVIA Holdings' track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include IQV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
